CTOs on the Move

Tonix Pharmaceuticals

www.tonixpharma.com

 
Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Tonix Pharmaceuticals raised $40M on 01/13/2021
Tonix Pharmaceuticals raised $70M on 02/08/2021

Similar Companies

Legacy Health System

Legacy Health System is an Oregon-based not-for-profit, tax-exempt corporation that includes five full-service hospitals and a children's hospital.

Response Biomedical Corporation

Response Biomedical Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Purigen Biosystems

Purigen Biosystems transformative platform provides a hands-free solution for extracting, enriching and quantifying DNA and RNA from biological samples.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.